University of Chicago Medicine entered into a research collaboration with Tempus — a health technology company focused on personalized oncology care — to improve pancreatic cancer treatment.
Tempus will work with a team of researchers and clinicians from the Chicago Pancreatic Cancer Initiative, led by Ralph Weichselbaum, MD, professor and chairman of the department of radiation oncology at the University of Chicago. Tempus will analyze data from CPCI — including biospecimen, genomic and clinical information — using machine learning and advanced bioinformatics.
The researchers hope the collaboration will uncover patterns in the clinical and molecular data to help providers better predict how individual pancreatic cancer patients will respond to treatment.
"The University of Chicago and Tempus share a commitment to accelerate pancreatic cancer research and identify treatments that can improve the lives of those diagnosed," Dr. Weichselbaum said. "We are optimistic that this collaboration can make a difference in the lives of those diagnosed and treated for pancreatic cancer."